5th Apr 2016 06:39
LONDON (Alliance News) - Pharmaceutical company BTG PLC on Tuesday said it expects revenue for the year to the end of March will hit the top end of its previous guidance.
BTG said revenue for the year to March 31 will be around the upper end of its GBP410.0 million to GBP440.0 million guidance range. Revenue for the prior financial year was GBP367.8 million.
BTG said revenue growth in its Interventional Oncology business has been in line with its expectations in constant currencies, with sales rising a mid-teen percentage, driven by sales of TheraSphere in the US and the initial impact of selling products through its direct sales force in Europe.
Sales of Varithena, BTG's varicose veins treatment, have been broadly flat year-on-year, and the group expects sales growth to rise in the new financial year on anticipated re-ordering by physicians.
Revenue from its PneumRx interventional pulmonology business also was broadly flat year-on-year, reflecting a flat performance in the German market.
Specialty pharmaceuticals sales, meanwhile, returned to single-digit growth following two years of sales growth exceeding 20%. Sales in the unit were driven by sales of snake bite treatment CroFab and toxicity treatment DigiFab.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG